Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial


Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer.

Related Videos
Michael Hagensee, MD, PhD, Louisiana State University Health, New Orleans School of Medicine